Special Issue

Tauopathies: New Perspectives and Challenges

Message from the Guest Editors

Tauopathies are a fascinating and vast assembly of neurodegenerative diseases, spanning multiple distinct neuropathological features, cellular phenotypes and clinical presentations. This diversity and complexity make tauopathies particularly challenging to model. Regardless, recent advancements in animal and cellular models have accelerated our knowledge and understanding of these diseases. In parallel, the development and application of new technologies to study and characterize these models have expanded our horizons for what is possible to know. However, we still have a long way to go with regard to untangling the complexity and pleiotropy of *MAPT*, tau and tauopathies, and developing effective therapies and treatments. We invite authors from any area of the tauopathy field to submit original research or review articles pertaining to this special issue. Studies and opinions on new approaches and technologies that have changed our perspective of the field, where we are currently lacking in our efforts and understanding, and the challenges we face to make meaningful progress are encouraged.

Guest Editors

Dr. Kathryn Bowles

UK Dementia Research Institute, University of Edinburgh, Edinburgh EH16 4SB, UK

Dr. Maria Catarina Silva

1. Center for Genomic Medicine, Chemical Neurobiology Laboratory, Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
2. Department of Neurology, Harvard Medical School, Boston, MA 02115, USA

Deadline for manuscript submissions

closed (31 March 2024)

Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/
biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).